LIQUAEMIN SODIUM PRESERVATIVE FREE (heparin sodium) by Aspen Surgical is protein, antithrombin iii, to induce a conformational change, which markedly enhances the serine protease activity of antithrombin ii, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly xa and iia. First approved in 1939.
Drug data last refreshed 19h ago · AI intelligence enriched 4w ago
LIQUAEMIN SODIUM PRESERVATIVE FREE is a preservative-free formulation of heparin sodium, an injectable anticoagulant that works by enhancing antithrombin III activity to inhibit coagulation factors Xa and IIa. It prevents thrombus formation in patients requiring anticoagulation but does not dissolve existing clots. This is a foundational anticoagulant with decades of clinical use in acute care and thromboprophylaxis.
As a legacy anticoagulant approaching loss of exclusivity with moderate competitive pressure, this product likely operates with a lean, highly efficient team focused on defending market share in hospital formulary channels.
protein, antithrombin III, to induce a conformational change, which markedly enhances the serine protease activity of Antithrombin II, thereby inhibiting the activated coagulation factors involved in the closing sequence, particularly Xa and IIa. Small amounts of heparin inhibit Factor Xa, and…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study With Heparin Sodium in Subcutaneous Administration
Study With Heparin Sodium in Intravenous Administration
Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)
Worked on LIQUAEMIN SODIUM PRESERVATIVE FREE at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Career opportunities on LIQUAEMIN are concentrated in hospital-channel expertise, formulary defense, and supply chain optimization rather than expansion or launch activities. Professionals in this space develop deep healthcare system relationships and specialized knowledge in anticoagulation protocols, making them valuable for portfolio roles spanning anticoagulants and critical care.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo